ATRX缺失促进IDH1突变胶质瘤的免疫抑制机制
研究在p53突变星形细胞瘤细胞系中建立可诱导的IDH1R132H及ATRX缺失等基因模型,发现ATRX缺失增强细胞侵袭性、上调BET蛋白BRD3/4及免疫检查点等免疫抑制转录组,促进T细胞凋亡、肿瘤相关巨噬细胞极化及Treg浸润,该效应可被替莫唑胺和放疗增强、被BET抑制剂逆转。
要点
- ATRX缺失联合IDH1R132H/p53突变促进星形细胞瘤细胞侵袭与致瘤性。
- ATRX缺失上调BRD3/4及PD-L1、PD-L2等免疫抑制转录组。
- BET抑制剂可逆转ATRX缺失诱导的免疫抑制转录与生物学效应。
核心结论
- ATRX缺失在IDH1R132H/p53突变星形细胞瘤细胞中激活BRD依赖的免疫抑制转录组和免疫逃逸机制。
研究设计与样本
- 在p53突变星形细胞瘤细胞系中利用慢病毒编码多西环素可诱导的IDH1R132H、ATRX shRNA或Lenti-CRISPR/Cas9 ATRX建立等基因细胞(+/-IDH1R132H/+/-ATRX缺失)。
主要发现
- 在IDH1R132H/p53mut背景中加入ATRX缺失促进星形细胞瘤细胞侵袭性,诱导BET蛋白BRD3/4表达及由免疫检查点(如PD-L1、PD-L2)上调和细胞因子/趋化因子谱(如IL33、CXCL8、CSF2、IL6、CXCL9)改变组成的免疫抑制转录组。
- ATRX缺失增强IDH1R132H/p53mut细胞诱导T细胞凋亡、致瘤/抗炎巨噬细胞极化和Treg浸润的能力。
- 对ATRX缺失的转录和生物学免疫抑制反应被替莫唑胺和放疗增强,并被药理学BET抑制消除。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ATRX inactivation occurs with IDH1R132H and p53 mutations in over 80% of Grades II/III astrocytomas. It is believed that ATRX loss contributes to oncogenesis by dysregulating epigenetic and telomere mechanisms but effects on anti-glioma immunity have not been explored. This paper examines how ATRX loss contributes to the malignant and immunosuppressive phenotypes of IDH1R132H/p53mut glioma cells and xenografts. METHODS: Isogenic astrocytoma cells (+/-IDH1R132H/+/-ATRXloss) were established in p53mut astrocytoma cell lines using lentivirus encoding doxycycline-inducible IDH1R132H, ATRX shRNA, or Lenti-CRISPR/Cas9 ATRX. Effects of IDH1R132H+/-ATRXloss on cell migration, growth, DNA repair, and tumorigenicity were evaluated by clonal growth, transwell and scratch assays, MTT, immunofluorence and immunoblotting assays, and xenograft growth. Effects on the expression and function of modulators of the immune microenvironment were quantified by qRT-PCR, immunoblot, T-cell function, macrophage polarization, and flow cytometry assays. Pharmacologic inhibitors were used to examine epigenetic drivers of the immunosuppressive transcriptome of IDH1R132H/p53mut/ATRXloss cells. RESULTS: Adding ATRX loss to the IDH1R132H/p53mut background promoted astrocytoma cell aggressiveness, induced expression of BET proteins BRD3/4 and an immune-suppressive transcriptome consisting of up-regulated immune checkpoints (e.g., PD-L1, PD-L2) and altered cytokine/chemokine profiles (e.g., IL33, CXCL8, CSF2, IL6, CXCL9). ATRX loss enhanced the capacity of IDH1R132H/p53mut cells to induce T-cell apoptosis, tumorigenic/anti-inflammatory macrophage polarization and Treg infiltration. The transcriptional and biological immune-suppressive responses to ATRX loss were enhanced by temozolomide and radiation and abrogated by pharmacologic BET inhibition. CONCLUSIONS: ATRX loss activates a BRD-dependent immune-suppressive transcriptome and immune escape mechanism in IDH1R132H/p53mut astrocytoma cells.
引用
- Hu C, Wang K, Damon C, et al. ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. Neuro Oncol. 2022. PMID: 34951647. doi:10.1093/neuonc/noab292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。